; (B) the manufacturer; (C) whether the drug was determined under section 2(b) to have an excessive price; and (D) the number of petitions the Secretary received under section 2(c) to make an excessive price determination for the drug, together with the information described in section 2(c)(3). (3) Certain determinations With respect to a determination made under section 2(b)(1), the Secretary shall publish on the database such determination in accordance with paragraph (1) within 30 days of receiving domestic and international pricing information from manufacturers under section 6. (b) Annual reports to Congress Not later than 60 days after the first excessive price review under section 2 is complete, and annually thereafter, the Secretary shall submit to Congress a report describing the excessive drug price review for the preceding year. The report shall contain summary data regarding— (1) the total number of drugs that were reviewed; (2) the total number of drugs determined to be excessively priced under each of paragraphs (1) and (2) of section 2(b), and the name and manufacturer of each such drug; (3) the total number of drugs determined to be excessively priced, listed by manufacturer; (4) the extent to which the prices of the drugs identified under section 2 were higher than reasonable, on average; (5) the total number of petitions the Secretary received under section 2(c) to make excessive price determinations for drugs; (6) a list of any manufacturers who failed to report information as required under section 6